SCHEMBL4771118

SCHEMBL4771118

COC(=O)c1ccc(CNS(=O)(=O)CCc2cccc(Cl)c2Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
POLB P06746 3/20 0.45
ALDH1A1 P00352 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.42
MAPT P10636 4/20 0.41
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CYP4A11 Q02928 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HPGD P15428 1/20 0.39
CYP4F2 P78329 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767669 0.80 MAPT (0.46) SMN1; SMN2POLBALDH1A1MAPTLMNA
SCHEMBL4771005 0.78 POLB (0.55) SMN1; SMN2NPSR1POLBALDH1A1MAPT
SCHEMBL4767769 0.78 MAPT (0.45) SMN1; SMN2NPSR1POLBALDH1A1MAPT
SCHEMBL4773551 0.75 PPARA (0.45) SMN1; SMN2NPSR1POLBALDH1A1L3MBTL1
SCHEMBL7229624 0.74 HPGD (0.61) POLBALDH1A1LOXL2MAPTLMNA
SCHEMBL4774741 0.74 HPGD (0.58) SMN1; SMN2POLBALDH1A1MAPTLMNA
SCHEMBL4773543 0.74 EPHX2 (0.42) SMN1; SMN2NPSR1ALDH1A1MAPTLMNA
SCHEMBL18424017 0.74 PKM (0.49) SMN1; SMN2POLBALDH1A1MAPTLMNA
SCHEMBL4771125 0.74 MAPT (0.55) SMN1; SMN2NPSR1POLBALDH1A1LOXL2
SCHEMBL4777535 0.74 PTGES2 (0.49) SMN1; SMN2POLBALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 SMN1; SMN2 1149/4885NPSR1 4395/4885POLB 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.